Neurocrine Biosciences, Inc. (NBIX)

Bayesian Capital Management LP bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) in the second quarter, according to the company in its most recent disclosure with the Securi...

California Public Employees Retirement System raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 3.9% during the second quarter, according to the company in its most recent 1...

SAN DIEGO , Dec. 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00 ...

Neurocrine Biosciences stock, part of the high-ranking biotech industry group, is trading back inside a buy zone....

Fisher Asset Management LLC lessened its stake in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 8.1% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exc...

Neurocrine Biosciences, Inc. (NBIX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript...

Capital Fund Management S.A. lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 15.9% during the undefined quarter, according to the company in its most recent 13F filing ...

Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth in financials....

Creative Planning lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 31.6% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. ...

Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight important differences between treatments Review pr...